This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Tandem Diabetes (TNDM) Releases Favorable Data on t:slim X2
by Zacks Equity Research
Tandem Diabetes (TNDM) demonstrated positive results from the clinical trial of advancing its Control-IQ technology to younger age group patients.
Medtronic's (MDT) Affera Ablation System Gets CE Mark
by Zacks Equity Research
Medtronic's (MDT) Affera Mapping and Ablation System is intended to treat atrial arrhythmias.
Abbott (ABT) Diabetes Arm Growth Robust Amid Macroeconomic Woes
by Zacks Equity Research
Abbott (ABT) currently forecasts total organic sales growth, excluding the impact of COVID testing-related sales, to be in the high-single digits in 2023.
Reasons Why You Should Retain ResMed (RMD) Stock For Now
by Zacks Equity Research
Investors are optimistic about ResMed's (RMD) Increased demand for its digital health solution.
Here's Why You Should Retain Walgreens Boots (WBA) For Now
by Zacks Equity Research
Investors are optimistic about Walgreens Boots (WBA), backed by continued partnership growth and a strong focus on strategic execution.
Masimo (MASI) PVi Achieves Acceptable Fluid Response in Study
by Zacks Equity Research
Masimo (MASI) PVi helps clinicians reliably predict fluid responsiveness in young neurosurgical patients.
Charles River's (CRL) New Cloud Platform Offers Real-Time Data
by Zacks Equity Research
Charles River (CRL) launches cloud-based platform Apollo which enhances decision making abilities by providing real-time Toxicology study data.
Illumina (ILMN) Unveils Complete Long Reads Technology
by Zacks Equity Research
Illumina's (ILMN) Complete Long Read Prep combines Illumina sequencing by synthesis chemistry with DRAGEN secondary analysis to provide WGS with more accuracy.
Syneos Health's (SYNH) Product Launch Aids, FX Woe Hurts
by Zacks Equity Research
Syneos Health (SYNH) remains confident about the long-term strength of its business, given its robust backlog and unique market position.
Here's Why Investors Should Retain LabCorp (LH) Stock for Now
by Zacks Equity Research
Investors are optimistic about LabCorp (LH) backed by strength in its Drug Development business.
Henry Schein (HSIC) Aids Growth of Ambulatory Surgery Centers
by Zacks Equity Research
Henry Schein (HSIC) joined ASCA as part of its commitment to augment the value of ambulatory surgery centers.
Henry Schein (HSIC) International Growth Solid, Dental Rebounds
by Zacks Equity Research
Henry Schein's (HSIC) distribution business boasts a wide global footprint with 61 distribution centers.
Charles River (CRL) Advances CDMO Portfolio With Latest Offer
by Zacks Equity Research
Charles River's (CRL) newest addition, pHelper plasmid, targets simplifying the complex supply chains and cutting production timelines.
Abbott (ABT) to Pair CGM Sensors & AID System on FDA Clearance
by Zacks Equity Research
Abbott Laboratories (ABT) receives FDA clearance for the integration of its iCGM system sensors with automated insulin delivery (AID) systems.
Charles River (CRL) Hurt by NHP Shipment Issue, FX Woes
by Zacks Equity Research
The investigation related to the current NHP supply situation is likely to result in study delays in Charles River's (CRL) Safety Assessment business.
Thermo Fisher (TMO) Introduces iCAP RQplus ICP-MS Analyzer
by Zacks Equity Research
Thermo Fisher's (TMO) new analyzer streamlines everyday analyses in environmental, food, pharmaceutical and industrial testing laboratories.
Here's Why You Should Retain CVS Health (CVS) Stock for Now
by Zacks Equity Research
Investors are optimistic about CVS Health (CVS), backed by the announcement of entering into a colossal $10.6-billion acquisition agreement to purchase Oak Street Health.
QIAGEN (QGEN) to Develop CDx Test for TIBSOVO With New Pact
by Zacks Equity Research
QIAGEN (QGEN) will develop a real-time in vitro PCR test that can be utilized to spot IDH1 gene mutations in AML patients in whole blood and bone marrow aspirates.
Here is Why Growth Investors Should Buy Haemonetics (HAE) Now
by Zacks Equity Research
Haemonetics (HAE) could produce exceptional returns because of its solid growth attributes.
Here's Why You Should Retain Bio-Rad (BIO) Stock for Now
by Zacks Equity Research
Investors are optimistic about Bio-Rad (BIO), owing to robust demand in Life Science and Clinical Diagnostics arms.
Thermo Fisher (TMO) Unveils New Line of Low-Flow HPLC Columns
by Zacks Equity Research
Thermo Fisher's (TMO) newest addition of a new line of low-flow HPLC columns that improve separation performance and stability of biologically complex samples.
Smith & Nephew (SNN) Simplifies ACL Surgery With New Offers
by Zacks Equity Research
Smith & Nephew (SNN) introduces QUADTRAC System and broadens ULTRABUTTON Adjustable Fixation Devices portfolio for ACL reconstruction.
Bio-Rad (BIO) Global Expansion Strong, FX Woe Dents Growth
by Zacks Equity Research
Bio-Rad (BIO) experiences double-digit currency-neutral core revenue growth in the Americas and Asia in Q4.
Abbott (ABT) Gets FDA Nod for Alinity I Laboratory Test
by Zacks Equity Research
Abbott's (ABT) Alinity i TBI lab test provides a new reliable result in 18 minutes to support clinicians in quickly assessing concussion and triaging patients.
LabCorp (LH) Focuses on High-Growth Areas Amid Currency Woe
by Zacks Equity Research
In its efforts to expand further, LabCorp (LH) is focusing more on high-growth opportunity areas such as neurodegenerative, autoimmune and liver disease as well as cell and gene therapy.